{
    "clinical_study": {
        "@rank": "163063", 
        "arm_group": [
            {
                "arm_group_label": "20 mg  Arm Cohort A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Arm Cohort A", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "5 mg Arm Cohort B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Arm Cohort B", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of\n      PF-0254920 in Subjects with Early Huntington's Disease."
        }, 
        "brief_title": "Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Huntington's Disease", 
        "condition_browse": {
            "mesh_term": "Huntington Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have a diagnosis of Huntington's Disease\n\n          -  a CAG repeat expansion equal or great than 39\n\n          -  a Unified Huntington Disease Rating Scale (UHDRS) Total Motor Score equal or greater\n             than 5 and less than 60\n\n          -  a UHDRS Total Functional Capacity equal or greater than 9\n\n        Exclusion Criteria:\n\n          -  Subjects with evidence or history of severe acute or chronic medical condition or\n             laboratory abnormality, or significant neurological disorder other than HD.\n\n          -  Treatment with any antipsychotic medication within 5 weeks of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806896", 
            "org_study_id": "A8241016"
        }, 
        "intervention": [
            {
                "arm_group_label": "20 mg  Arm Cohort A", 
                "description": "Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach  20 mg from Days 7 to Day28.\nOrally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.\nTreatment for 28 days.", 
                "intervention_name": "PF-02545920", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm Cohort A", 
                "description": "- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.\nDosing for 28 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Arm Cohort B", 
                "description": "5mg dose\nOrally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.\nDosing for 28 days.", 
                "intervention_name": "PF-02545920", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm Cohort B", 
                "description": "Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.\nDosing for 28 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8241016&StudyName=Study%20Evaluating%20The%20Safety%2C%20Tolerability%20And%20Brain%20Function%20Of%202%20Doses%20Of%20PF-0254920%20In%20Subjects%20With%20Early%20Huntington%u2019s%20Disease"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris Cedex 13", 
                    "country": "France", 
                    "zip": "75651"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Double-Blind Randomized, Sequential Treatment Group, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-Striatal Function Of 2 Doses Of PF-02545920 In Subjects With Early Huntington's Disease", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The UHDRS is a clinical rating scale which has been developed by the Huntington Disease Study Group (HSG) to provide a uniform assessment of the clinical features and course of HD. the Total Motor Score (TMS) is one of the six sub components of UHDRS.", 
            "measure": "Change from Baseline to Day 28 of Unified Huntington Disease Rating Scale -Total Motor Score (TMS)", 
            "safety_issue": "Yes", 
            "time_frame": "Screening, Day 1, Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806896"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The monetary incentive delay (MID) task is established as a reliable method to elicit ventral striatal activity in relation to reward/punishment anticipation and tracked with dysfunctionalities across a range of conditions in which incentive motivation is thought to be abnormal (schizophrenia, depression, substance abuse, and pathological gambling). Pharmacological intervention has demonstrated reversal of observed deficit.", 
                "measure": "Change from Baseline to Day28 in fMRI parameter estimates and percent signal change  during Monetary Incentive Delay", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day28"
            }, 
            {
                "description": "This incentive force task was developed to independently dissociate the degree to which a subject responds to reward motivation versus emotional motivation, as well as a subject's perception of difficulty level in performing a given task.", 
                "measure": "Change from Baseline to Day28 in Grip Strength Incentive Motivation task score", 
                "safety_issue": "No", 
                "time_frame": "Baseline predose, Baseline postdose, Day28"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}